A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma

Haematologica

Volumn 88, Issue 2, 2003, Pages 176-185

  Vacca, Angelo ^a,d   Ria, Roberto ^a   Ribatti, Domenico ^a   Semeraro, Fabrizio ^a   Djonov, Valentin ^b   Di Raimondo, Francesco ^c   Dammacco, Franco ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF CATANIA   (Italy)

^d POLICLINICO   (Italy)

Author keywords

Angiogenesis; Endothelial cells; Multiple myeloma; Stromal cells; Tumor growth; Vascular endothelial growth factor

Indexed keywords

CYANOCOBALAMIN; IRON; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; SIGNAL PEPTIDE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD VESSEL PERMEABILITY; BONE MARROW CELL; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CHEMOTAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYANOCOBALAMIN DEFICIENCY; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; GAMMOPATHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IRON DEFICIENCY ANEMIA; MALE; MULTIPLE MYELOMA; NEOVASCULARIZATION (PATHOLOGY); PARACRINE SIGNALING; PLASMA CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN TARGETING; CELL DIVISION; METABOLISM; MIDDLE AGED; PATHOLOGY; SECRETION; TISSUE DISTRIBUTION; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; CELL DIVISION; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PARACRINE COMMUNICATION; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0038284068     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001;280:C1358-C66.
2. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-83.
3. Olofsson B, Jeltsch M, Eriksson U, Alitalo K. Current biology of VEGF-B and VEGF-C. Curr Opin Biotechnol 1999;10:528-35.
4. Witmer AN, Van Blijswijk BC, Dai J, Hofman P, Partanen TA, Vrensen GF, et al. VEGFR-3 in adult angiogenesis. J Pathol 2001;195:490-7.
5. Larrivee B, Karsan A. Signaling pathways induced by vascular endothelial growth factor. Int J Mol Med 2000;5:447-56.
6. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-8.
7. Skobe M, Hamberg LM, Hawighorst T, Schirner M, Wolf GL, Alitalo K, et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 2001;159:893-903.
8. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, et al. Induction of tumor lymphanglogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7:192-8.
9. Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001;7:199-205.
10. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999;59:728-33.
11. Bellamy WT. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol 2001;28:551-9.
12. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001;98:428-35.
13. Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P, et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 2000;85:800-5.
14. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000;95:2630-6.
15. Durie BGM, Salmon SE. Multiple myeloma, macroglobulinemia and monoclonal gammapathies. In: Hoffbrand AV, Brain MC, Hirsh J, editors. Recent Advances in Hematology. New York, NY: Churchill Livingstone; 1977. p. 243-61.
16. Vacca A, Ribatti D, Presta M, Minischetti M, lurlaro M, Ria R, et al. Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064-73.
17. Billadeau D, Ahmann G, Greipp P, Van Ness B. The bone marrow of multiple myeloma patients contains B-cell populations at different stages of differentiation that are clonally related to malignant plasma cells. J Exp Med 1993;178:1023-31.
18. Dominici M, Campioni D, Lanza F, Luppi M, Barozzi P, Pauli S, et al. Angiogenesis in multiple myeloma: correlation between in vitro endothelial colonies growth (CFU-Em) and clinical-biological features. Leukemia 2001;15:171-6.
19. Valdembri D, Serini G, Vacca A, Ribatti D, Bussolino F. In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J 2002;16:225-7.
20. Herley MT, Yu Y, Whitney RG, Sato JD. Characterization of the VEGF binding site on the Flt-1 receptor. Biochem Biophys Res Commun 1999;262:731-8.
21. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992;187:1579-86.
22. Aprelikova O, Pajusola K, Partanen J, Armstrong E, Alitalo R, Bailey SK, et al. FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter. Cancer Res 1992;52:746-8.
23. Vacca A, Ria R, Presta M, Ribatti D, lurlaro M, Merchionne F, et al. αVβ3 integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells. Exp Hematol 2001;29:993-1003.
24. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989;73:517-26.
25. Kueng W, Silber E, Eppenberger U. Quantification of cells cultured on 96-well plates. Anal Biochem 1989;182:16-9.
26. Borset M, Seidel C, Hjorth-Hansen H, Waage A, Sundan A. The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. Leuk Lymphoma 1999;32:249-56.
27. Barillé S, Bataille R, Amiot M. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-α complex in the pathogenesis of multiple myeloma. Eur Cytokine Netw 2000;11:546-51.
28. Klein B. Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma. Semin Hematol 1995;32:4-19.
29. Ribatti D, Vacca A, Nico B, Crivellato E, Roncali L, Dammacco F. The role of mast cells in tumour angiogenesis. Br J Haematol 2001;115:514-21.
30. Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor (VEGF). Oncogene 1995;10:135-47.
31. Kroll J, Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 1997;272:32521-7.
32. Ortega N, L'Faqihi FE, Plouet J. Control of vascular endothelial growth factor angiogenic activity by the extracellular matrix. Biol Cell 1998;90:381-90.
33. Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 2001;86:23-33.
34. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002;8:2210-6.
35. Sezer O, Niemoller K, Kaufmann O, Eucker J, Jakob C, Zavrski I, et al. Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. Eur J Haematol 2001;66:238-44.
36. Laroche M, Brousset P, Ludot I, Mazieres B, Thiechart M, Attal M. Increased vascularization in myeloma. Eur J Haematol 2001;66:89-93.
37. Moehler M, Neben K, Ho D, Goldschmidt H. Angiogenesis in hematologic malignancies. Ann Hematol 2001;80:695-705.
38. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-8.
39. Ribatti D, Nico B, Morbidelli L, Donnini S, Ziche M, Vacca A, et al. Cell-mediated delivery of fibroblast growth factor-2 and vascular endothelial growth factor onto the chick chorioallantoic membrane: endothelial fenestration and angiogenesis. J Vasc Res 2001;38:389-97.
40. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62-6.
41. Vacca A, Frigeri A, Ribatti D, Nicchia GP, Nico B, Ria R, et al. Microvessel overexpression of aquaporin 1 parallels bone marrow angiogenesis in patients with active multiple myeloma. Br J Haematol 2001;113:415-21.
42. Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997;89:1870-5.
43. Dias S, Choy M, Alitalo K, Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 2002;99:2179-84.
44. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995;92:7686-9.
45. Podar K, Tai YT, Lin BK, Narsimhan RP, Sattler M, Kijima T, et al. Vascular endothelial growth factor (VEGF)-induced migration of multiple myeloma cells is associated with β1-integrin- and P13-kinase-dependent PKCα activation. J Biol Chem 2002;277:7875-81.
46. Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF, et al. Vascular permeability factor (vascular endothelial growth factor) expression in cervical neoplasia. J Natl Cancer Inst 1995;87:1237-45.
47. Abu-Jawdeh G, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasm. Lab Invest 1996;74:1105-15.
48. Chow NH, Hsu PI, Lin XZ, Yang HB, Chan SH, Cheng KS, et al. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hum Path 1997;28:698-703.
49. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002;99:1745-57.
50. Sezer O, Jacob C, Euker J, Niemoller K, Gatz F, Wernecke K, et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001;66:83-8.
51. Iwasaki T. Hamano T, Ogata A, Hashimoto N, Kitano M, Kakishita E. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol 2002;116:796-802.
52. Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001;28:607-12.